CL2023002895A1 - Anticuerpos anti-il-2r agonistas y métodos de uso - Google Patents

Anticuerpos anti-il-2r agonistas y métodos de uso

Info

Publication number
CL2023002895A1
CL2023002895A1 CL2023002895A CL2023002895A CL2023002895A1 CL 2023002895 A1 CL2023002895 A1 CL 2023002895A1 CL 2023002895 A CL2023002895 A CL 2023002895A CL 2023002895 A CL2023002895 A CL 2023002895A CL 2023002895 A1 CL2023002895 A1 CL 2023002895A1
Authority
CL
Chile
Prior art keywords
antibodies
methods
agonist antibodies
compositions
il2rb
Prior art date
Application number
CL2023002895A
Other languages
English (en)
Inventor
Trinklein Nathan
Harris Katherine
LORENTSEN Kyle
Kaur MALIK CHAUDHRY Harbani
LOUGHLIN Kaitlyn
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of CL2023002895A1 publication Critical patent/CL2023002895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se divulgan anticuerpos anti-IL2R (por ejemplo, anti-IL2RB, anti-IL2RG, anti-IL2RB/G), junto con métodos de elaboración de estos anticuerpos, composiciones, incluidas composiciones farmacéuticas, que comprenden estos anticuerpos, y el uso de los anticuerpos y composiciones en el tratamiento de enfermedades y trastornos que se median por la vía de señalización de IL2/IL2R.
CL2023002895A 2021-04-02 2023-09-28 Anticuerpos anti-il-2r agonistas y métodos de uso CL2023002895A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170383P 2021-04-02 2021-04-02
US202163239883P 2021-09-01 2021-09-01

Publications (1)

Publication Number Publication Date
CL2023002895A1 true CL2023002895A1 (es) 2024-02-02

Family

ID=81385128

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002895A CL2023002895A1 (es) 2021-04-02 2023-09-28 Anticuerpos anti-il-2r agonistas y métodos de uso

Country Status (14)

Country Link
US (2) US11884735B2 (es)
EP (1) EP4314067A1 (es)
JP (1) JP2024512982A (es)
KR (1) KR20230165263A (es)
AU (1) AU2022252398A1 (es)
BR (1) BR112023020219A2 (es)
CA (1) CA3214587A1 (es)
CL (1) CL2023002895A1 (es)
CO (1) CO2023014054A2 (es)
CR (1) CR20230507A (es)
IL (1) IL305944A (es)
TW (1) TW202304994A (es)
UY (1) UY39715A (es)
WO (1) WO2022212848A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005880XA (en) 2017-12-22 2020-07-29 Teneobio Inc Heavy chain antibodies binding to cd22
AR119746A1 (es) 2019-06-14 2022-01-05 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US6297028B1 (en) 1995-01-09 2001-10-02 Boehringer Ingelheim International Gmbh IL-2R-associated polypeptide and DNA molecules coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1997043416A1 (en) 1996-05-10 1997-11-20 Biogen, Inc. Common gamma chain blocking agents
US6103879A (en) 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
PL374586A1 (en) 2002-10-10 2005-10-31 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
LT2406284T (lt) 2009-03-10 2016-10-10 Biogen Ma Inc. Antikūnai prieš b ląstelių subrendimo antigenus
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
US11059910B2 (en) 2012-12-03 2021-07-13 Novimmune Sa Anti-CD47 antibodies and methods of use thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US10472421B2 (en) 2015-08-06 2019-11-12 Agency For Science, Technology And Research Method for expansion of a population of cells with IL2R beta/common gamma chain antibodies
KR20190053835A (ko) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 Cd3 결합 항체
CA3034706A1 (en) 2016-08-24 2018-03-01 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
WO2019092181A1 (en) 2017-11-10 2019-05-16 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies
WO2020094834A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
WO2020094836A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
EP3917962A1 (en) 2019-02-01 2021-12-08 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins

Also Published As

Publication number Publication date
TW202304994A (zh) 2023-02-01
KR20230165263A (ko) 2023-12-05
US20230242653A1 (en) 2023-08-03
CO2023014054A2 (es) 2023-11-10
JP2024512982A (ja) 2024-03-21
CA3214587A1 (en) 2022-10-06
US20240018250A1 (en) 2024-01-18
AU2022252398A9 (en) 2024-01-11
AU2022252398A1 (en) 2023-09-21
UY39715A (es) 2022-10-31
BR112023020219A2 (pt) 2024-02-06
CR20230507A (es) 2023-12-12
EP4314067A1 (en) 2024-02-07
IL305944A (en) 2023-11-01
US11884735B2 (en) 2024-01-30
WO2022212848A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
CL2023002895A1 (es) Anticuerpos anti-il-2r agonistas y métodos de uso
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2020002419A1 (es) Inhibidores de fosfatasa shp2 y métodos de uso de los mismos
AR112969A1 (es) Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
AR074227A1 (es) Anticuerpos contra il-6 y uso de los mismos
ECSP055679A (es) Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf)
PA8583101A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
CO6410303A2 (es) Nicotinamidas sustituidas como moduladores de kcnq2/3
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PE20230431A1 (es) Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas
CL2022002963A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CO2021007581A2 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteínas de los mismos para usarse como agonistas de lxr
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CO2023013500A2 (es) Anticuerpos anti-cd19 y estructuras car-t
CO2023013543A2 (es) Anticuerpos anti-cd20 y estructuras car-t
CL2023001220A1 (es) Inhibidores de interleucina-17
CL2023001432A1 (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
WO2022183074A3 (en) Anti-psma antibodies and car-t structures
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo